This paper reports preliminary experiences with human recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) in children with malignant diseases administered for three indications: (1) chemotherapy-induced neutropenia and sepsis, (2) prolonged neutropenia decreasing dose intensity, and (3) prevention of neutropenia after sublethal doses of chemotherapy. It was concluded that in the daily dose of 5 micrograms/kg subcutaneously, GM-CSF is capable of reducing the duration of chemotherapy-induced neutropenia and may be an effective tool in maintaining dose intensity and achieving dose escalation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/08880019409141657 | DOI Listing |
Publication Analysis
Top Keywords
human recombinant
8
recombinant granulocyte-macrophage
8
granulocyte-macrophage colony-stimulating
8
colony-stimulating factor
8
chemotherapy-induced neutropenia
8
dose intensity
8
factor pediatric
4
pediatric oncology
4
oncology practice
4
practice paper
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!